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To The Editor 
 
I read with great interest the recent papers authored by Rahimi [1], published in this journal, and by Guest and 
colleagues [2], published in Medicine & Science in Sport & Exercise, exploring the ergogenic effects of caffeine 
on different CYP1A2 genotypes. Briefly, Rahimi reported 6mg/kg of caffeine did not enhance resistance 
exercise performance in C allele carriers in a cohort of males, but did for AA genotypes. Similarly, Guest et al. 
[2] found that caffeine was ergolytic for endurance performance at a dose of 4mg/kg for CC genotypes, was 
ergogenic at doses of both 2- and 4mg/kg for AA genotypes, and neutral for AC genotypes at both doses, as 
well as for CC genotypes at 2mg/kg. Since 2012, a number of papers have been published exploring the impact 
of this particular polymorphism on caffeine’s performance benefits, with equivocal results [3,4]. These previous 
studies tended to be hindered by complex study designs [4], or low subject numbers [3]. The latter point is 
particularly important, given that the frequency of CC genotypes tends to be very low (~8%) [2], illustrated by 
the complete absence of CC genotypes available for group analysis in Rahimi’s cohort [1]. As such, the 
additional insights garnered from both Rahimi [1] and Guest and colleagues [2] shed further insight into the 
inter-individual variation of ergogenic effects following caffeine ingestion.  
 
The results, however, promote significant cognitive dissonance. As an AC genotype who used caffeine 
extensively as an ergogenic aid during my professional athletic career, do I really believe that caffeine had no 
performance benefits for me? It’s hard for me to reach such a conclusion, even though the results of both 
Rahimi and Guest and colleagues’ research [1,2] suggest as much. I’m sure many other practitioners feel the 
same, and indeed perhaps worry that the standard caffeine recommendations are harmful, or at best neutral, for a 
significant proportion of the athletes they work with [5]. 
 
The mechanism proposed by Guest et al. [2] is that, because C allele carriers metabolise caffeine at a slower rate 
than AA genotypes [6], they experience prolonged vasoconstriction, which is likely to be performance limiting 
in endurance events where the transfer of oxygen and nutrients to the working muscle is crucial. Additionally, 
Womack and colleagues [3] speculated that the metabolites of caffeine – paraxanthine, theobromine, and 
theophylline – have additional ergogenic effects; in this case, the presence of these ergogenic substances would 
be lower in C allele carriers at a given time point due to the slower metabolization of caffeine, reducing 
caffeine’s performance benefits. This proposed mechanism was echoed by Rahimi [1].  
 
If the above mechanisms are indeed correct, then there remains the possibility that caffeine can still be 
ergogenic for C allele carriers, but that such individuals need to consume it a greater amount of time prior to 
exercise. In the majority of studies – including Guest et al. [2] and Rahimi [1] – subjects consume caffeine ~60 
minutes pre-exercise. However, for C allele carriers, could the ergogenic effects of caffeine be restored by 
utilizing a caffeine dose 90 or 120 minutes pre-exercise? Such an hypothesis is, of course, speculative, and 
requires testing – but it does represent a potential way by which caffeine can indeed be ergogenic for all. The 
resolution of whether caffeine is truly ergolytic or neutral for CYP1A2 C allele carriers, or if it merely 
necessitates a different caffeine strategy, represents an important step on the journey towards more personalized 
sports nutrition guidelines.  
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